Yee Chan‐Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yee Chan‐Li has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Alexander T. Hillel
Department of Otolaryngology‐Head and Neck Surgery Johns Hopkins School of Medicine Baltimore Maryland USA
6 shared publications - Kevin M. Motz
Department of Otolaryngology – Head and Neck Surgery Johns Hopkins University School of Medicine Baltimore Maryland USA
6 shared publications - Ioan Lina
Department of Otolaryngology Head and Neck Surgery Johns Hopkins University School of Medicine Baltimore Maryland U.S.A.
4 shared publications Samuel L. Collins
Department of Otolaryngology – Head and Neck Surgery Johns Hopkins Hospital Baltimore Maryland USA
4 shared publications- Alexander Gelbard
Vanderbilt University Medical Center, Nashville
3 shared publications - Laura M. Mafla
Department of Otolaryngology Head and Neck Surgery Johns Hopkins University School of Medicine Baltimore Maryland USA
3 shared publications
Latest Publications
- 10 June 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (10) , 4361-4368
Idiopathic Subglottic Stenosis in Pregnancy: A Case–Control Study of Management and Maternal Safety
Objective: To evaluate safety and clinical course in pregnant idiopathic subglottic stenosis (iSGS) patients and to identify variables associated with operative dilation requirement during pregnancy. Background: Pregnancy in patients with iSGS presents management challenges that may impact maternal and fetal health. Clinical studies and shared experiences are limited. Methods: A retrospective chart review was conducted evaluating pregnant iSGS patients and an age‐matched never pregnant iSGS control group. Pregnant patients were subcategorized based on whether they required surgery during pregnancy. The analyzed variables included demographics, inter‐dilation intervals, time to first recurrence, intraoperative stenosis percent, and fetal and maternal safety. Results: Thirty‐three patients were included, 23 in the pregnancy group, and 10 in the control group. Thirteen patients required operative intervention during pregnancy. The mean age at iSGS diagnosis was 31.1 years. All pregnancies resulted in live births. No surgical or anesthesia‐related complications were reported. Antinuclear antibody (ANA) positivity was more frequent in the surgical‐intervention group compared to the nonintervention group (5/10 vs. 0, p < 0.05). The overall inter‐dilation interval was longer in the pregnancy group compared to the control group (median: 70.9 vs. 39.6 weeks, p < 0.05) Average stenosis percentages in surgical dilations during and prior to pregnancy were comparable (60.4 ± 21.6 vs. 55.2 ± 27.8). Conclusion: Surgical management of iSGS patients is safe during pregnancy. Greater than 50% patients experienced exacerbation during pregnancy that required operative intervention. The only notable patient‐specific factor associated with dilation during pregnancy was ANA positivity. There were no pregnancy‐specific factors associated with the need for intervention. Level of Evidence: 3.
- 10 June 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (10) , 4361-4368
Idiopathic Subglottic Stenosis in Pregnancy: A Case–Control Study of Management and Maternal Safety
Objective: To evaluate safety and clinical course in pregnant idiopathic subglottic stenosis (iSGS) patients and to identify variables associated with operative dilation requirement during pregnancy. Background: Pregnancy in patients with iSGS presents management challenges that may impact maternal and fetal health. Clinical studies and shared experiences are limited. Methods: A retrospective chart review was conducted evaluating pregnant iSGS patients and an age‐matched never pregnant iSGS control group. Pregnant patients were subcategorized based on whether they required surgery during pregnancy. The analyzed variables included demographics, inter‐dilation intervals, time to first recurrence, intraoperative stenosis percent, and fetal and maternal safety. Results: Thirty‐three patients were included, 23 in the pregnancy group, and 10 in the control group. Thirteen patients required operative intervention during pregnancy. The mean age at iSGS diagnosis was 31.1 years. All pregnancies resulted in live births. No surgical or anesthesia‐related complications were reported. Antinuclear antibody (ANA) positivity was more frequent in the surgical‐intervention group compared to the nonintervention group (5/10 vs. 0, p < 0.05). The overall inter‐dilation interval was longer in the pregnancy group compared to the control group (median: 70.9 vs. 39.6 weeks, p < 0.05) Average stenosis percentages in surgical dilations during and prior to pregnancy were comparable (60.4 ± 21.6 vs. 55.2 ± 27.8). Conclusion: Surgical management of iSGS patients is safe during pregnancy. Greater than 50% patients experienced exacerbation during pregnancy that required operative intervention. The only notable patient‐specific factor associated with dilation during pregnancy was ANA positivity. There were no pregnancy‐specific factors associated with the need for intervention. Level of Evidence: 3.
- 8 August 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (1) , 251-261
S100A8 / A9 Promotes Fibrosis in Iatrogenic Laryngotracheal Stenosis
Objective: Iatrogenic Laryngotracheal Stenosis (iLTS) is a pathologic narrowing of the laryngotracheal airway secondary to intubation injury. Inflammation plays a critical role in iLTS pathogenesis. However, the local immune mediators promoting inflammation and subsequent fibrosis remain poorly understood. Transcriptomic analysis of iLTS specimens using single‐cell RNA sequencing has revealed increased expression of the damage‐associated molecular pattern (DAMP), S100A8/A9. The goal of this study is to define the role of S100A8/A9 in iLTS pathogenesis in vivo. Methods: S100A8/A9 expression was assessed using single‐cell RNA sequencing and immunofluorescence in human iLTS and unaffected tracheal controls. To assess the fibrogenicity of S100A8/A9, iLTS‐induced mice were treated with recombinant S100A8/A9 (0.1 mg/kg) or a vehicle control. Fibrosis was assessed by measurement of tracheal lamina propria (LP) thickness and fibrosis‐related gene expression. Results: Immunofluorescence of human iLTS specimens demonstrated increased expression of S100A8/A9 in the LP compared to controls. In iLTS‐induced mice, S100A8/A9 treatment resulted in greater LP thickness compared to control‐treated mice (117.7 ± 23.72 vs. 67.7 ± 33.11 μM, p = 0.03). Gene expression analysis demonstrated a 4.42 ± 0.73 fold increase in Col1a1 expression in S100A8/A9‐treated iLTS mice ( p = 0.01). S100A8/A9's downstream regulatory protein MYD88 is increased in human iLTS and in iLTS mice treated with S100A8/A9. Conclusion: S100A8/A9 is abundant in human iLTS and promotes fibrosis in a murine model. Targeting S100A8/A9 and its downstream signaling protein MYD88 may be an effective treatment strategy to attenuate iLTS. Investigation into therapies that target S100A8/A9 signaling is warranted. Level of Evidence: NA.
- 8 August 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (1) , 251-261
S100A8 / A9 Promotes Fibrosis in Iatrogenic Laryngotracheal Stenosis
Objective: Iatrogenic Laryngotracheal Stenosis (iLTS) is a pathologic narrowing of the laryngotracheal airway secondary to intubation injury. Inflammation plays a critical role in iLTS pathogenesis. However, the local immune mediators promoting inflammation and subsequent fibrosis remain poorly understood. Transcriptomic analysis of iLTS specimens using single‐cell RNA sequencing has revealed increased expression of the damage‐associated molecular pattern (DAMP), S100A8/A9. The goal of this study is to define the role of S100A8/A9 in iLTS pathogenesis in vivo. Methods: S100A8/A9 expression was assessed using single‐cell RNA sequencing and immunofluorescence in human iLTS and unaffected tracheal controls. To assess the fibrogenicity of S100A8/A9, iLTS‐induced mice were treated with recombinant S100A8/A9 (0.1 mg/kg) or a vehicle control. Fibrosis was assessed by measurement of tracheal lamina propria (LP) thickness and fibrosis‐related gene expression. Results: Immunofluorescence of human iLTS specimens demonstrated increased expression of S100A8/A9 in the LP compared to controls. In iLTS‐induced mice, S100A8/A9 treatment resulted in greater LP thickness compared to control‐treated mice (117.7 ± 23.72 vs. 67.7 ± 33.11 μM, p = 0.03). Gene expression analysis demonstrated a 4.42 ± 0.73 fold increase in Col1a1 expression in S100A8/A9‐treated iLTS mice ( p = 0.01). S100A8/A9's downstream regulatory protein MYD88 is increased in human iLTS and in iLTS mice treated with S100A8/A9. Conclusion: S100A8/A9 is abundant in human iLTS and promotes fibrosis in a murine model. Targeting S100A8/A9 and its downstream signaling protein MYD88 may be an effective treatment strategy to attenuate iLTS. Investigation into therapies that target S100A8/A9 signaling is warranted. Level of Evidence: NA.
- 27 November 2024
- Published by Wiley in The Laryngoscope
- Vol. 135 (5) , 1724-1731
Serum S100A8 / A9 Correlates to Surgery‐Free Interval in Idiopathic Subglottic Stenosis
Objective: Idiopathic subglottic stenosis (iSGS) is a progressive fibrotic condition of the subglottis that presents in women of northern European descent. Endoscopic dilation is a common surgical approach to management of iSGS. The surgery‐free interval, or the time between endoscopic dilation procedures is considered an indicator of disease severity. Variations in surgery‐free intervals among iSGS patients underscore the necessity for prognostic biomarkers. The objective of this study was to explore serum levels of the damage‐associated molecular pattern S100A8/A9 as a prognostic biomarker in iSGS. Methods: Serum from 20 iSGS patients and eight healthy controls was collected and S100A8/A9 levels were quantified using an ELISA. Patient data, including demographics and surgery‐free intervals, were obtained from medical records. Serum S100A8/A9 levels were compared to surgery‐free intervals. S100A8/A9 was also assessed using gene expression and immunofluorescence in iSGS specimens. Results: S100A8/A9 was significantly elevated ( p = 0.0413) in the serum of iSGS patients compared to controls (312.75 vs. 181.49 ng/mL). Linear regression analysis revealed a correlation ( p = 0.009) between S100A8/A9 levels and endoscopic surgery‐free interval. S100A8/A9 was significantly elevated ( p = 0.0011) in patients with surgery‐free intervals less than 1 year (455.2 ± 60.45 ng/mL; n = 8) compared to patients with intervals over 1 year (292.5.93 ± 162.4; n = 6). Conclusion: S100A8/A9 is increased in the serum and tissue of patients with iSGS. In this cohort of iSGS patients, serum S100A8/A9 was associated with surgery‐free intervals, potentially representing a prognostic biomarker. Further research within a larger cohort is needed to confirm these findings. Level of Evidence: 3 Laryngoscope , 135:1724–1731, 2025
- 27 November 2024
- Published by Wiley in The Laryngoscope
- Vol. 135 (5) , 1724-1731
Serum S100A8 / A9 Correlates to Surgery‐Free Interval in Idiopathic Subglottic Stenosis
Objective: Idiopathic subglottic stenosis (iSGS) is a progressive fibrotic condition of the subglottis that presents in women of northern European descent. Endoscopic dilation is a common surgical approach to management of iSGS. The surgery‐free interval, or the time between endoscopic dilation procedures is considered an indicator of disease severity. Variations in surgery‐free intervals among iSGS patients underscore the necessity for prognostic biomarkers. The objective of this study was to explore serum levels of the damage‐associated molecular pattern S100A8/A9 as a prognostic biomarker in iSGS. Methods: Serum from 20 iSGS patients and eight healthy controls was collected and S100A8/A9 levels were quantified using an ELISA. Patient data, including demographics and surgery‐free intervals, were obtained from medical records. Serum S100A8/A9 levels were compared to surgery‐free intervals. S100A8/A9 was also assessed using gene expression and immunofluorescence in iSGS specimens. Results: S100A8/A9 was significantly elevated ( p = 0.0413) in the serum of iSGS patients compared to controls (312.75 vs. 181.49 ng/mL). Linear regression analysis revealed a correlation ( p = 0.009) between S100A8/A9 levels and endoscopic surgery‐free interval. S100A8/A9 was significantly elevated ( p = 0.0011) in patients with surgery‐free intervals less than 1 year (455.2 ± 60.45 ng/mL; n = 8) compared to patients with intervals over 1 year (292.5.93 ± 162.4; n = 6). Conclusion: S100A8/A9 is increased in the serum and tissue of patients with iSGS. In this cohort of iSGS patients, serum S100A8/A9 was associated with surgery‐free intervals, potentially representing a prognostic biomarker. Further research within a larger cohort is needed to confirm these findings. Level of Evidence: 3 Laryngoscope , 135:1724–1731, 2025
- 13 May 2024
- Published by Wiley in The Laryngoscope
- Vol. 134 (10) , 4239-4245
An Ovine Model Yields Histology and Gene Expression Changes Consistent with Laryngotracheal Stenosis
Objectives: Animal models for laryngotracheal stenosis (LTS) are critical to understand underlying mechanisms and study new therapies. Current animal models for LTS are limited by small airway sizes compared to human. The objective of this study was to develop and validate a novel, large animal ovine model for LTS.Methods: Sheep underwent either bleomycin‐coated polypropylene brush injury to the subglottis (n = 6) or airway stent placement (n = 2) via suspension microlaryngoscopy. Laryngotracheal complexes were harvested 4 weeks following injury or stent placement. For the airway injury group, biopsies (n = 3 at each site) were collected of tracheal scar and distal normal regions, and analyzed for fibrotic gene expression. Lamina propria (LP) thickness was compared between injured and normal areas of trachea.Results: No mortality occurred in sheep undergoing airway injury or stent placement. There was no migration of tracheal stents. After protocol optimization, LP thickness was significantly increased in injured trachea (Sheep #3: 529.0 vs. 850.8 um; Sheep #4: 933.0 vs. 1693.2 um; Sheep #5: 743.7 vs. 1378.4 um; Sheep #6: 305.7 vs. 2257.6 um). A significant 62‐fold, 20‐fold, 16‐fold, 16‐fold, and 9‐fold change of COL1, COL3, COL5, FN1, and TGFB1 was observed in injured scar specimen relative to unaffected airway, respectively.Conclusion: An ovine LTS model produces histologic and transcriptional changes consistent with fibrosis seen in human LTS. Airway stent placement in this model is safe and feasible. This large airway model is a reliable and reproducible method to assess the efficacy of novel LTS therapies prior to clinical translation.Level of Evidence: N/A Laryngoscope, 134:4239–4245, 2024
- 13 May 2024
- Published by Wiley in The Laryngoscope
- Vol. 134 (10) , 4239-4245
An Ovine Model Yields Histology and Gene Expression Changes Consistent with Laryngotracheal Stenosis
Objectives: Animal models for laryngotracheal stenosis (LTS) are critical to understand underlying mechanisms and study new therapies. Current animal models for LTS are limited by small airway sizes compared to human. The objective of this study was to develop and validate a novel, large animal ovine model for LTS.Methods: Sheep underwent either bleomycin‐coated polypropylene brush injury to the subglottis (n = 6) or airway stent placement (n = 2) via suspension microlaryngoscopy. Laryngotracheal complexes were harvested 4 weeks following injury or stent placement. For the airway injury group, biopsies (n = 3 at each site) were collected of tracheal scar and distal normal regions, and analyzed for fibrotic gene expression. Lamina propria (LP) thickness was compared between injured and normal areas of trachea.Results: No mortality occurred in sheep undergoing airway injury or stent placement. There was no migration of tracheal stents. After protocol optimization, LP thickness was significantly increased in injured trachea (Sheep #3: 529.0 vs. 850.8 um; Sheep #4: 933.0 vs. 1693.2 um; Sheep #5: 743.7 vs. 1378.4 um; Sheep #6: 305.7 vs. 2257.6 um). A significant 62‐fold, 20‐fold, 16‐fold, 16‐fold, and 9‐fold change of COL1, COL3, COL5, FN1, and TGFB1 was observed in injured scar specimen relative to unaffected airway, respectively.Conclusion: An ovine LTS model produces histologic and transcriptional changes consistent with fibrosis seen in human LTS. Airway stent placement in this model is safe and feasible. This large airway model is a reliable and reproducible method to assess the efficacy of novel LTS therapies prior to clinical translation.Level of Evidence: N/A Laryngoscope, 134:4239–4245, 2024
- Open Access
- 1 June 2023
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 7 (6) , 493-507
Serendipitous Discovery of T Cell–Produced KLK1b22 as a Regulator of Systemic Metabolism
In order to study mechanistic/mammalian target of rapamycin’s role in T cell differentiation, we generated mice in which Rheb is selectively deleted in T cells (T-Rheb−/− C57BL/6J background). During these studies, we noted that T-Rheb−/− mice were consistently heavier but had improved glucose tolerance and insulin sensitivity as well as a marked increase in beige fat. Microarray analysis of Rheb−/− T cells revealed a marked increase in expression of kallikrein 1–related peptidase b22 (Klk1b22). Overexpression of KLK1b22 in vitro enhanced insulin receptor signaling, and systemic overexpression of KLK1b22 in C57BL/6J mice also enhances glucose tolerance. Although KLK1B22 expression was markedly elevated in the T-Rheb−/− T cells, we never observed any expression in wild-type T cells. Interestingly, in querying the mouse Immunologic Genome Project, we found that Klk1b22 expression was also increased in wild-type 129S1/SVLMJ and C3HEJ mice. Indeed, both strains of mice demonstrate exceptionally improved glucose tolerance. This prompted us to employ CRISPR-mediated knockout of KLK1b22 in 129S1/SVLMJ mice, which in fact led to reduced glucose tolerance. Overall, our studies reveal (to our knowledge) a novel role for KLK1b22 in regulating systemic metabolism and demonstrate the ability of T cell–derived KLK1b22 to regulate systemic metabolism. Notably, however, further studies have revealed that this is a serendipitous finding unrelated to Rheb.
- 1 June 2023
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 7 (6) , 493-507
Open AccessSerendipitous Discovery of T Cell–Produced KLK1b22 as a Regulator of Systemic Metabolism
In order to study mechanistic/mammalian target of rapamycin’s role in T cell differentiation, we generated mice in which Rheb is selectively deleted in T cells (T-Rheb−/− C57BL/6J background). During these studies, we noted that T-Rheb−/− mice were consistently heavier but had improved glucose tolerance and insulin sensitivity as well as a marked increase in beige fat. Microarray analysis of Rheb−/− T cells revealed a marked increase in expression of kallikrein 1–related peptidase b22 (Klk1b22). Overexpression of KLK1b22 in vitro enhanced insulin receptor signaling, and systemic overexpression of KLK1b22 in C57BL/6J mice also enhances glucose tolerance. Although KLK1B22 expression was markedly elevated in the T-Rheb−/− T cells, we never observed any expression in wild-type T cells. Interestingly, in querying the mouse Immunologic Genome Project, we found that Klk1b22 expression was also increased in wild-type 129S1/SVLMJ and C3HEJ mice. Indeed, both strains of mice demonstrate exceptionally improved glucose tolerance. This prompted us to employ CRISPR-mediated knockout of KLK1b22 in 129S1/SVLMJ mice, which in fact led to reduced glucose tolerance. Overall, our studies reveal (to our knowledge) a novel role for KLK1b22 in regulating systemic metabolism and demonstrate the ability of T cell–derived KLK1b22 to regulate systemic metabolism. Notably, however, further studies have revealed that this is a serendipitous finding unrelated to Rheb.
- Open Access
- 12 January 2023
- Published by Wiley in The Laryngoscope
- Vol. 133 (9) , 2346-2356
Myeloid Phenotypes in Tracheostomy‐Associated Granulation Tissue
Objective(s): Tracheostomy‐associated granulation tissue is a common, recurrent problem occurring secondary to chronic mucosal irritation. Although granulation tissue is composed of predominantly innate immune cells, the phenotype of monocytes and macrophages in tracheostomy‐associated granulation tissue is unknown. This study aims to define the myeloid cell population in granulation tissue secondary to tracheostomy.Methods: Granulation tissue biopsies were obtained from 8 patients with tracheostomy secondary to laryngotracheal stenosis. Cell type analysis was performed by flow cytometry and gene expression was measured by quantitative real‐time polymerase chain reaction. These methods and immunohistochemistry were used to define the monocyte/macrophage population in granulation tissue and were compared to tracheal autopsy control specimens.Results: Flow cytometry demonstrated macrophages (CD45+CD11b+) and monocytes (CD45+FSClowSSClow) represent 23.2 ± 6% of the granulation tissue cell population. The M2 phenotype (CD206) is present in 77 ± 11% of the macrophage population and increased compared to the M1 phenotype (p = 0.012). Classical monocytes (CD45+CD14highCD16low) were increased in granulation tissue compared to controls (61.2 ± 7% and 30 ± 8.5%, p = 0.038). Eighty‐five percent of macrophages expressed pro‐inflammatory S100A8/A9 and 36 ± 4% of macrophages co‐localized CD169, associated with tissue‐resident macrophages. M2 gene expression (Arg1/CD206) was increased in granulation tissue (3.7 ± 0.4, p = 0.035 and 3.5 ± 0.5, p = 0.047) whereas M1 gene expression (CD80/CD86) was similar to controls (p = 0.64, p = 0.3). Immunohistochemistry of granulation tissue demonstrated increased cells co‐localizing CD11b and CD206.Conclusions: M2 macrophages are the dominant macrophage phenotype in tracheostomy‐associated granulation tissue. The role of this cell type in promoting ongoing inflammation warrants future investigation to identify potential treatments for granulation tissue secondary to tracheostomy.Level of Evidence: 3 Laryngoscope, 133:2346–2356, 2023
- 12 January 2023
- Published by Wiley in The Laryngoscope
- Vol. 133 (9) , 2346-2356
Open AccessMyeloid Phenotypes in Tracheostomy‐Associated Granulation Tissue
Objective(s): Tracheostomy‐associated granulation tissue is a common, recurrent problem occurring secondary to chronic mucosal irritation. Although granulation tissue is composed of predominantly innate immune cells, the phenotype of monocytes and macrophages in tracheostomy‐associated granulation tissue is unknown. This study aims to define the myeloid cell population in granulation tissue secondary to tracheostomy.Methods: Granulation tissue biopsies were obtained from 8 patients with tracheostomy secondary to laryngotracheal stenosis. Cell type analysis was performed by flow cytometry and gene expression was measured by quantitative real‐time polymerase chain reaction. These methods and immunohistochemistry were used to define the monocyte/macrophage population in granulation tissue and were compared to tracheal autopsy control specimens.Results: Flow cytometry demonstrated macrophages (CD45+CD11b+) and monocytes (CD45+FSClowSSClow) represent 23.2 ± 6% of the granulation tissue cell population. The M2 phenotype (CD206) is present in 77 ± 11% of the macrophage population and increased compared to the M1 phenotype (p = 0.012). Classical monocytes (CD45+CD14highCD16low) were increased in granulation tissue compared to controls (61.2 ± 7% and 30 ± 8.5%, p = 0.038). Eighty‐five percent of macrophages expressed pro‐inflammatory S100A8/A9 and 36 ± 4% of macrophages co‐localized CD169, associated with tissue‐resident macrophages. M2 gene expression (Arg1/CD206) was increased in granulation tissue (3.7 ± 0.4, p = 0.035 and 3.5 ± 0.5, p = 0.047) whereas M1 gene expression (CD80/CD86) was similar to controls (p = 0.64, p = 0.3). Immunohistochemistry of granulation tissue demonstrated increased cells co‐localizing CD11b and CD206.Conclusions: M2 macrophages are the dominant macrophage phenotype in tracheostomy‐associated granulation tissue. The role of this cell type in promoting ongoing inflammation warrants future investigation to identify potential treatments for granulation tissue secondary to tracheostomy.Level of Evidence: 3 Laryngoscope, 133:2346–2356, 2023
- 16 December 2022
- Published by Wiley in The Laryngoscope
- Vol. 133 (9) , 2308-2316
Characterizing the Macrophage Population in Patients With Idiopathic Subglottic Stenosis
Objectives: Idiopathic subglottic stenosis (iSGS) is characterized by progressive fibrosis and subglottic luminal narrowing. Currently, immune characterization has focused on T‐cells; however, macrophages remain largely unexplored. The goals of this study are to characterize the transcriptome of iSGS macrophages and the fibrogenic nature of identifed biomarkers.Study Design: Bioinformatics and in vitro.Methods: Human tracheal biopsies from iSGS scar (n = 4), and matched non‐scar (n = 4) regions were analyzed using single‐cell RNA‐seq (scRNA‐seq). Immunofluorescence (IF) was performed on rapidly processed autopsies (RPA) and iSGS tracheal resections (n = 4) to co‐localize S100A8/9 and CD11b. Collagen gene/protein expression was assessed in iSGS fibroblasts (n = 4) treated with protein S100A8/9 (1000 ng/ml). Macrophages were subclustered to identify distinct subpopulations.Results: scRNA‐seq analysis revealed S100A8/S100A9 (fold change (FC) = 4.1/1.88, p < 0.001) as top differentially expressed genes in iSGS macrophages. IF exhibited increased CD11b+/S100A8/9+ cells in tracheal samples of iSGS versus RPA (26.75% ± 7.08 vs. 0.594% ± 0.974, n = 4, p = 0.029). iSGS fibroblasts treated with S100A8/9 demonstrated increased gene expression of COL1A1 (FC = 2.30 ± 0.45, p = 0.03, n = 4) and COL3A1 (FC = 2.44 ± 0.40, p = 0.03, n = 4). COL1A1 protein assays revealed an increase in the experimental group, albeit not significant, (p = 0.12, n = 4). Finally, macrophage sub clustering revealed one subpopulation as a predominant source of S100A8/S100A9 expression (FC = 7.94/5.47, p < 0.001).Conclusions: S100A8/9 is a key biomarker in iSGS macrophages. Although S100A8/9 demonstrates profibrotic nature in vitro, the role of S100A8/9+ macrophages in vivo warrants further investigation.Level of Evidence: NA Laryngoscope, 133:2308–2316, 2023
- 16 December 2022
- Published by Wiley in The Laryngoscope
- Vol. 133 (9) , 2308-2316
Characterizing the Macrophage Population in Patients With Idiopathic Subglottic Stenosis
Objectives: Idiopathic subglottic stenosis (iSGS) is characterized by progressive fibrosis and subglottic luminal narrowing. Currently, immune characterization has focused on T‐cells; however, macrophages remain largely unexplored. The goals of this study are to characterize the transcriptome of iSGS macrophages and the fibrogenic nature of identifed biomarkers.Study Design: Bioinformatics and in vitro.Methods: Human tracheal biopsies from iSGS scar (n = 4), and matched non‐scar (n = 4) regions were analyzed using single‐cell RNA‐seq (scRNA‐seq). Immunofluorescence (IF) was performed on rapidly processed autopsies (RPA) and iSGS tracheal resections (n = 4) to co‐localize S100A8/9 and CD11b. Collagen gene/protein expression was assessed in iSGS fibroblasts (n = 4) treated with protein S100A8/9 (1000 ng/ml). Macrophages were subclustered to identify distinct subpopulations.Results: scRNA‐seq analysis revealed S100A8/S100A9 (fold change (FC) = 4.1/1.88, p < 0.001) as top differentially expressed genes in iSGS macrophages. IF exhibited increased CD11b+/S100A8/9+ cells in tracheal samples of iSGS versus RPA (26.75% ± 7.08 vs. 0.594% ± 0.974, n = 4, p = 0.029). iSGS fibroblasts treated with S100A8/9 demonstrated increased gene expression of COL1A1 (FC = 2.30 ± 0.45, p = 0.03, n = 4) and COL3A1 (FC = 2.44 ± 0.40, p = 0.03, n = 4). COL1A1 protein assays revealed an increase in the experimental group, albeit not significant, (p = 0.12, n = 4). Finally, macrophage sub clustering revealed one subpopulation as a predominant source of S100A8/S100A9 expression (FC = 7.94/5.47, p < 0.001).Conclusions: S100A8/9 is a key biomarker in iSGS macrophages. Although S100A8/9 demonstrates profibrotic nature in vitro, the role of S100A8/9+ macrophages in vivo warrants further investigation.Level of Evidence: NA Laryngoscope, 133:2308–2316, 2023
- 1 August 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (3) , 913-922
mTORC1 Signaling Regulates Proinflammatory Macrophage Function and Metabolism
Metabolic programming is integrally linked to immune cell function. Nowhere is this clearer than in the differentiation of macrophages. Proinflammatory M1 macrophages primarily use glycolysis as a rapid energy source but also to generate antimicrobial compounds, whereas alternatively activated M2 macrophages primarily rely on oxidative phosphorylation for the longevity required for proper wound healing. mTOR signaling has been demonstrated to be a key regulator of immune cell metabolism and function. mTORC2 signaling is required for the generation of M2 macrophages, whereas the role of mTORC1 signaling, a key regulator of glycolysis, has been controversial. By using genetic deletion of mTORC1 signaling in C57BL/6 mouse macrophages, we observed enhanced M1 macrophage function in vitro and in vivo. Surprisingly, this enhancement occurred despite a significant defect in M1 macrophage glycolytic metabolism. Mechanistically, enhanced M1 function occurred because of inhibition of the class III histone deacetylases the sirtuins, resulting in enhanced histone acetylation. Our findings provide a counterpoint to the paradigm that enhanced immune cell function must occur in the presence of increased cellular metabolism and identifies a potential, pharmacologic target for the regulation of inflammatory responses.
- 1 August 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (3) , 913-922
mTORC1 Signaling Regulates Proinflammatory Macrophage Function and Metabolism
Metabolic programming is integrally linked to immune cell function. Nowhere is this clearer than in the differentiation of macrophages. Proinflammatory M1 macrophages primarily use glycolysis as a rapid energy source but also to generate antimicrobial compounds, whereas alternatively activated M2 macrophages primarily rely on oxidative phosphorylation for the longevity required for proper wound healing. mTOR signaling has been demonstrated to be a key regulator of immune cell metabolism and function. mTORC2 signaling is required for the generation of M2 macrophages, whereas the role of mTORC1 signaling, a key regulator of glycolysis, has been controversial. By using genetic deletion of mTORC1 signaling in C57BL/6 mouse macrophages, we observed enhanced M1 macrophage function in vitro and in vivo. Surprisingly, this enhancement occurred despite a significant defect in M1 macrophage glycolytic metabolism. Mechanistically, enhanced M1 function occurred because of inhibition of the class III histone deacetylases the sirtuins, resulting in enhanced histone acetylation. Our findings provide a counterpoint to the paradigm that enhanced immune cell function must occur in the presence of increased cellular metabolism and identifies a potential, pharmacologic target for the regulation of inflammatory responses.
- Open Access
- 5 January 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (2) , 297-307
CNS-targeted autoimmunity leads to increased influenza mortality in mice
The discovery that central nervous system (CNS)–targeted autoreactive T cells required a process of licensing in the lung revealed an unexpected relationship between these organs. The clinical and immunological significance of this finding is bidirectional in that it showed not only a mechanism by which T cells become pathogenic before entering the CNS, but also the potential for this process to influence lung immunity as well. Epidemiological studies have shown that people with multiple sclerosis (MS) suffer from increased morbidity and mortality from infectious diseases, independent of immunosuppressive therapies. Respiratory infections account for a large percentage of deaths of people with MS. In this study, to investigate the mechanisms responsible for this enhanced susceptibility, we established a comorbid model system in which mice with experimental autoimmune encephalomyelitis (EAE) were administered a sublethal dose of influenza. Whereas mice with either EAE alone or influenza alone survived, 70% of comorbid mice died as a result of uncontrolled viral replication. Immunological analyses revealed that the induction of EAE led to a surprising alteration of the lung milieu, converting an effective stimulatory influenza-reactive environment into a suppressive one. These results provide mechanistic information that may help to explain the unexpected immunological interactions.
- 5 January 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (2) , 297-307
Open AccessCNS-targeted autoimmunity leads to increased influenza mortality in mice
The discovery that central nervous system (CNS)–targeted autoreactive T cells required a process of licensing in the lung revealed an unexpected relationship between these organs. The clinical and immunological significance of this finding is bidirectional in that it showed not only a mechanism by which T cells become pathogenic before entering the CNS, but also the potential for this process to influence lung immunity as well. Epidemiological studies have shown that people with multiple sclerosis (MS) suffer from increased morbidity and mortality from infectious diseases, independent of immunosuppressive therapies. Respiratory infections account for a large percentage of deaths of people with MS. In this study, to investigate the mechanisms responsible for this enhanced susceptibility, we established a comorbid model system in which mice with experimental autoimmune encephalomyelitis (EAE) were administered a sublethal dose of influenza. Whereas mice with either EAE alone or influenza alone survived, 70% of comorbid mice died as a result of uncontrolled viral replication. Immunological analyses revealed that the induction of EAE led to a surprising alteration of the lung milieu, converting an effective stimulatory influenza-reactive environment into a suppressive one. These results provide mechanistic information that may help to explain the unexpected immunological interactions.